WO2023021479 - A SYNERGISTIC POLY HERBAL FORMULATION FOR TREATING VIRAL INFECTIONS AND A PROCESS OF PREPARATION THEREOF

National phase entry is expected:
Publication Number WO/2023/021479
Publication Date 23.02.2023
International Application No. PCT/IB2022/057810
International Filing Date 19.08.2022
Title **
[English] A SYNERGISTIC POLY HERBAL FORMULATION FOR TREATING VIRAL INFECTIONS AND A PROCESS OF PREPARATION THEREOF
[French] FORMULATION SYNERGIQUE COMPRENANT PLUSIEURS PLANTES, DESTINÉE AU TRAITEMENT D'INFECTIONS VIRALES ET SON PROCÉDÉ DE PRÉPARATION
Applicants **
ALAKART BIOPHARMA INC.
Inventors
REDDY, Ramgopal
MUTHU, Hari
Priority Data
202111022421   19.08.2021   IN
202111022422   19.08.2021   IN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting2009
EPO Filing, Examination, Granting11598
Japan Filing, Examination, Granting1983
South Korea Filing, Examination, Granting1763
USA Filing, Examination, Granting5510
MasterCard Visa
Total: 22,863

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] , and a process of preparation thereof. The cost effective immune-supporting formulation is ideal for use during the maintenance phase of the treatment, following an initial viral load reduction phase in which it is used as an adjuvant to conventional anti-viral drug therapy. Additionally, this formulation is used for treating and prevention of COVID-19.[French] , et un procédé de préparation associé. La formulation de soutien immunitaire économique est idéale pour une utilisation pendant la phase d'entretien du traitement, suite à une phase initiale de réduction de la charge virale dans laquelle elle est utilisée en tant qu'adjuvant pour une thérapie médicamenteuse antivirale classique. De plus, cette formulation est utilisée pour le traitement et la prévention du COVID-19.

Rejoining the server...